Association of polymorphisms in microRNA-binding sites and colorectal cancer in an Iranian population

Cancer Genetics

Volumn 205, Issue 10, 2012, Pages 501-507

  Azimzadeh, Pedram ^a   Romani, Sara ^a   Mohebbi, Seyed Reza ^a   Mahmoudi, Touraj ^a   Vahedi, Mohsen ^a   Fatemi, Seyed Reza ^a   Zali, Narges ^a   Zali, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; IL 16; MicroRNAs

Indexed keywords

ADENINE; CYTOSINE; MICRORNA; THYMINE;

3' UNTRANSLATED REGION; ADULT; ARTICLE; ASIAN; BINDING SITE; CANCER GENETICS; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; IRANIAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE CDKN2A; ONCOGENE IL 16; ONCOGENE ITGB4; ONCOGENE PTGER4; ONCOGENE RAF1; POPULATION BASED CASE CONTROL STUDY; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RNA BINDING;

ADULT; AGED; BINDING SITES; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATION; INTEGRIN BETA4; INTERLEUKIN-16; IRAN; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-RAF; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84867677327     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2012.05.013     Document Type: Article

References (47)

1. Stewart B.W., Kleihues P. World Cancer Report 2003, IARC Press, Lyon, France.
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Moghimi-Dehkordi B., Safaee A., Zali M.R. Prognostic factors in 1,138 Iranian colorectal cancer patients. Int J Colorectal Dis 2008, 23:683-688.
4. Delgado M.D., Leon J. Gene expression regulation and cancer. Clin Transl Oncol 2006, 8:780-787.
5. Basu A., Datta D., Zurakowski D., et al. Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem 2010, 285:25196-25202.
6. Benjamin D., Moroni C. mRNA stability and cancer: an emerging link?. Expert Opin Biol Ther 2007, 7:1515-1529.
7. Chen K., Song F., Calin G.A., et al. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 2008, 29:1306-1311.
8. Landi D., Gemignani F., Barale R., et al. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol 2008, 27:35-43.
9. Fang Z., Rajewsky N. The impact of miRNA target sites in coding sequences and in 3'UTRs. PLoS One 2011, 6:e18067.
10. Xiong F., Wu C., Chang J., et al. Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res 2011, 71:5175-5181.
11. Gao L.B., Rao L., Wang Y.Y., et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 2009, 30:295-299.
12. McWilliams R.R., Wieben E.D., Rabe K.G., et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet 2011, 19:472-478.
13. Brendle A., Lei H., Brandt A., et al. Polymorphisms in predicted microRNA-binding sites in integrin genes and breast cancer: ITGB4 as prognostic marker. Carcinogenesis 2008, 29:1394-1399.
14. Murn J., Alibert O., Wu N., et al. Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. J Exp Med 2008, 205:3091-3103.
15. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacothe 2001, 55:111-116.
16. Noser J.A., Mael A.A., Sakuma R., et al. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 2007, 15:1531-1536.
17. Abou-Zeid A.A., Azzam A.Z., Kamel N.A. Methylation status of the gene promoter of cyclin-dependent kinase inhibitor 2a (CDKN2a) in ovarian cancer. Scand J Clin Lab Invest 2011, 71:542-547.
18. Arima Y., Hayashi N., Hayashi H., et al. Loss of P16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 2012, 130:2568-2579.
19. Sambrook J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y, Page 6.4. J. Sambrook, D.W. Russell (Eds.).
20. Gazouli M., Atsaves V., Mantzaris G., et al. Role of functional polymorphisms of NRAMP1 gene for the development of Crohn's disease. Inflamm Bowel Dis 2008, 14:1323-1330.
21. Shen J., Ambrosone C.B., DiCioccio R.A., et al. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis 2008, 29:1963-1966.
22. Tian T., Xu Y., Dai J., et al. Functional polymorphisms in two pre-microRNAs and cancer risk: a meta-analysis. Int J Mol Epidemiol Genet 2010, 1:358-366.
23. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
24. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
25. He H., Jazdzewski K., Li W., et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 2005, 102:19075-19080.
26. Shaw L.M. Integrin function in breast carcinoma progression. J Mammary Gland Biol Neoplasia 1999, 4:367-376.
27. Guo W., Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004, 5:816-826.
28. Catalano R.D., Wilson M.R., Boddy S.C., et al. Hypoxia and prostaglandin E receptor 4 signalling pathways synergise to promote endometrial adenocarcinoma cell proliferation and tumour growth. PLoS One 2011, 6:e19209.
29. Mutoh M., Watanabe K., Kitamura T., et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002, 62:28-32.
30. Segi E., Sugimoto Y., Yamasaki A., et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998, 246:7-12.
31. Chandramouli A., Onyeagucha B.C., Mercado-Pimentel M.E., et al. MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther 2012, 13:175-183.
32. Wu J., Zhang Y., Frilot N., et al. Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 Receptor-Rap GTPase signal transduction pathway. J Biol Chem 2011, 286:33954-33962.
33. Regan J.W. EP2 and EP4 prostanoid receptor signaling. Life Sciences 2003, 74:143-153.
34. George R.J., Sturmoski M.A., Anant S., et al. EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 2007, 83:112-120.
35. Thakur N., Hussain S., Nasare V., et al. Association analysis of p16 (CDKN2A) and RB1 polymorphisms with susceptibility to cervical cancer in Indian population. Mol Biol Rep 2012, 39:407-414.
36. Rodriguez-Viciana P., Tetsu O., Oda K., et al. Cancer targets in the Ras pathway. Cold Spring Harb Symp Quant Biol 2005, 70:461-467.
37. Mathy N., Scheuer W., Lanzendörfer M., et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 2000, 100:63-69.
38. Grivennikov S.I., Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Annals Rheum Dis 2011, 70:i104-i108.
39. Landi D., Gemignani F., Naccarati A., et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 2008, 29:579-584.
40. Navarro A., Diaz T., Martinez A., et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009, 114:2945-2951.
41. Chen X., Guo X., Zhang H., et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28:1385-1392.
42. Gu X.-J., Cui B., Zhao Z.-F., et al. Association of the interleukin (IL)-16 gene polymorphisms with Graves' disease. Clin Immunol 2008, 127:298-302.
43. Iorio M.V., Ferracin M., Liu C.G., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
44. Fransén K., Klintenäs M., österström A., et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004, 25:527-533.
45. Miwa W., Yasuda J., Yashima K., et al. Absence of activating mutations of the RAF1 protooncogene in human lung cancer. Biol Chem Hoppe Seyler 1994, 375:705-709.
46. Simon R., Richter J., Wagner U., et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 2001, 61:4514-4519.
47. Azimzadeh P., Romani S., Mohebbi S.R., et al. Interleukin-16 (IL-16) gene polymorphisms in Iranian patients with colorectal cancer. J Gastrointestin Liver Dis 2011, 20:1-6.